Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it will be presenting at three ophthalmology industry conferences in the coming weeks. Eleven will participate in a discussion with experts on dry eye disease and will review Phase 1b/2a clinical data on its lead drug candidate EBI-005 for dry eye disease and preclinical data on EBI-029 for diabetic macular edema.
Help employers find you! Check out all the jobs and post your resume.
